Plenge Robert M
- SEC CIK
- 0001773367
No open-market purchases or sales filed in the past year.
Current role at each company
- BMRN Biomarin Pharmaceutical IncDirectoras of Sep 14, 2026
- BMY Bristol Myers Squibb CoEVP, Chief Research Officeras of Mar 12, 2026
- Translate Bio, Inc.Directoras of Sep 14, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Plenge Robert M as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
BMY Bristol Myers Squibb Co
EVP, Chief Research Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2023 (view filing) | Aug 3 | 4 days | Plenge Robert MEVP, Chief Research Officer | SSaleCommon Stock, $0.10 par value | −732 | $61.14 | −$44.8K | −10.0%6.58K after |
Translate Bio, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2021 (view filing) | Sep 14 | Same day | Plenge Robert MDirector | SSale | −95.6K | $0.00 | $0 | –0 after | Derivative4 lots |